Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317296 | 0.89 | DRD2 (0.41) | DRD2DRD3GRIN2BKMT2AMEN1 | |
| SCHEMBL5746496 | 0.87 | GRIN2B (0.44) | DRD2DRD3GRIN2BFUCA1ALDH1A1 | |
| SCHEMBL5747642 | 0.86 | HSD11B1 (0.44) | DRD2DRD3GRIN2BKMT2AMEN1 | |
| SCHEMBL6319234 | 0.78 | GRIN2B (0.49) | GRIN2BFUCA1ALDH1A1 | |
| SCHEMBL2801968 | 0.78 | SCN4A (0.43) | DRD2DRD3GRIN2BKMT2ASIGMAR1 | |
| SCHEMBL6311508 | 0.77 | KDM4E (0.41) | GRIN2BSIGMAR1ALDH1A1POLB | |
| SCHEMBL5748184 | 0.77 | HSD11B1 (0.41) | DRD2DRD3GRIN2BKMT2AMEN1 | |
| SCHEMBL6310196 | 0.76 | CACNA1G (0.44) | GRIN2BSIGMAR1POLB | |
| SCHEMBL5745277 | 0.76 | TACR1 (0.39) | — | |
| SCHEMBL6309643 | 0.75 | DRD2 (0.47) | DRD2DRD3GRIN2BKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | DRD2 701/4885DRD3 948/4885GRIN2B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.